Mereo Total Current Liabilities vs Total Liab Analysis
| MREO Stock | USD 4.25 0.04 0.95% |
Mereo BioPharma financial indicator trend analysis is infinitely more than just investigating Mereo BioPharma Group recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mereo BioPharma Group is a good investment. Please check the relationship between Mereo BioPharma Total Current Liabilities and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Total Current Liabilities vs Total Liab
Total Current Liabilities vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mereo BioPharma Group Total Current Liabilities account and Total Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Mereo BioPharma's Total Current Liabilities and Total Liab is 0.53. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Liab in the same time period over historical financial statements of Mereo BioPharma Group, assuming nothing else is changed. The correlation between historical values of Mereo BioPharma's Total Current Liabilities and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Mereo BioPharma Group are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Current Liabilities i.e., Mereo BioPharma's Total Current Liabilities and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.53 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Total Current Liabilities
Total Current Liabilities is an item on Mereo BioPharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mereo BioPharma Group are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Mereo BioPharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Mereo BioPharma's Issuance Of Capital Stock is very stable compared to the past year. As of the 31st of October 2024, Sales General And Administrative To Revenue is likely to grow to 1.93, while Tax Provision is likely to drop (558.6 K).
Mereo BioPharma fundamental ratios Correlations
Click cells to compare fundamentals
Mereo BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mereo BioPharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 86.4M | 62.9M | 126.4M | 88.1M | 66.5M | 70.1M | |
| Short Long Term Debt Total | 32.4M | 17.9M | 16.8M | 12.8M | 6.0M | 5.7M | |
| Other Current Liab | 354K | 4.6M | 1.3M | 10.0M | 30K | 28.5K | |
| Total Current Liabilities | 29.9M | 8.6M | 12.5M | 24.7M | 9.5M | 14.3M | |
| Total Stockholder Equity | 40.3M | (15.0M) | 88.0M | 61.9M | 50.5M | 44.6M | |
| Other Liab | 1.6M | 52.1M | 9.7M | 311K | 357.7K | 339.8K | |
| Net Tangible Assets | (4.2M) | (46.6M) | 63.4M | 37.8M | 43.4M | 45.6M | |
| Property Plant And Equipment Net | 11.6M | 1.6M | 2.5M | 1.8M | 1.7M | 2.4M | |
| Net Debt | 16.1M | (5.5M) | (77.5M) | (43.6M) | (51.5M) | (54.0M) | |
| Retained Earnings | (146.1M) | (309.7M) | (297.0M) | (331.2M) | (419.6M) | (398.6M) | |
| Accounts Payable | 6.4M | 3.3M | 2.3M | 3.1M | 2.3M | 2.8M | |
| Cash | 16.3M | 23.5M | 94.3M | 56.3M | 57.4M | 55.8M | |
| Non Current Assets Total | 56.0M | 33.2M | 27.1M | 25.9M | 2.7M | 2.6M | |
| Non Currrent Assets Other | (56.0M) | (33.2M) | (27.1M) | (25.9M) | (23.4M) | (24.5M) | |
| Long Term Debt | 5.4M | 16.1M | 14.4M | 4.4M | 5.1M | 4.8M | |
| Cash And Short Term Investments | 16.3M | 23.5M | 94.3M | 56.3M | 57.4M | 41.0M | |
| Net Receivables | 12.0M | 4.6M | 1.8M | 2.7M | 3.7M | 4.2M | |
| Common Stock Total Equity | 213.3K | 213.7K | 294K | 1.0M | 1.2M | 1.2M | |
| Common Stock Shares Outstanding | 89.4M | 339.0M | 555.3M | 603.2M | 659.5M | 692.4M | |
| Short Term Investments | 544K | 547K | 569K | 51.1M | 58.8M | 61.7M | |
| Liabilities And Stockholders Equity | 86.4M | 62.9M | 126.4M | 88.1M | 66.5M | 70.1M | |
| Non Current Liabilities Total | 16.3M | 69.4M | 25.9M | 1.5M | 6.5M | 6.2M | |
| Capital Lease Obligations | 11.9M | 1.8M | 2.4M | 1.7M | 1.6M | 2.4M | |
| Inventory | (12.0M) | (4.6M) | (1.8M) | (2.7M) | 1.2M | 1.3M | |
| Other Current Assets | 14.1M | 6.3M | 5.0M | 5.8M | 1.4M | 1.3M | |
| Other Stockholder Equity | 138.7M | 160.5M | 246.3M | 253.2M | 484.9M | 509.1M | |
| Total Liab | 46.2M | 77.9M | 38.4M | 26.2M | 16.0M | 15.2M | |
| Property Plant And Equipment Gross | 13.3M | 1.6M | 4.1M | 3.4M | 2.5M | 3.1M | |
| Short Long Term Debt | 1.9M | 6.8M | 15.1M | 11.1M | 12.7M | 6.4M | |
| Total Current Assets | 30.4M | 29.7M | 99.3M | 62.1M | 63.8M | 64.2M | |
| Accumulated Other Comprehensive Income | 47.3M | 133.2M | 136.9M | 137.9M | (17.5M) | (16.6M) | |
| Non Current Liabilities Other | 44K | 62K | 80K | 182K | 764K | 802.2K | |
| Short Term Debt | 17.7M | 636K | 622K | 11.6M | 652K | 619.4K | |
| Intangible Assets | 44.5M | 31.6M | 24.6M | 24.1M | 1.1M | 1.0M | |
| Common Stock | 294K | 1.0M | 1.8M | 1.9M | 2.8M | 2.9M | |
| Property Plant Equipment | 11.6M | 1.6M | 2.5M | 1.8M | 2.1M | 2.5M | |
| Current Deferred Revenue | (177.7K) | 5.4M | 8.4M | 6.5M | 7.4M | 4.4M | |
| Net Invested Capital | 60.8M | 1.2M | 102.4M | 73.0M | 54.9M | 49.1M |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Mereo Stock
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.